- NSE
- GLENMARK
- BSE
- 532296
- ISIN
- INE935A01035
GLENMARK PHARMACEUTICALS
Healthcare· Pharmaceuticals & Biotechnology· Pharmaceuticals
₹2,671.10
+₹81.10 (+3.13%)
NSE close ·
GLENMARK PHARMACEUTICALS closed at ₹2,671.10 on 9 Nov 2026, up 3.13% on the day, and is up 47.45% over the past year.
Price history
Between 10 Nov 2025 and 9 Nov 2026, the closing price ranged from ₹1,817.30 to ₹2,671.10.
Price returns, excl. dividends. 3Y, 5Y and Max are annualised.
Fundamentals
- Market cap
- ₹75,385 Cr
- P/E (TTM)
- 52.0
- Industry P/E
- 35.5
- EPS (TTM)
- ₹51.41
- P/B
- 6.72
- Book value
- ₹397.29
- ROE
- 10.3%
- ROCE
- 17.4%
- Debt/equity
- 0.08
- Operating margin
- 10.8%
- Net margin
- 7.3%
- Dividend yield
- 0.09%
Market cap, P/E, P/B and yield at the 9 Nov 2026 close. TTM: four quarters to 30 Sep 2026 (consolidated). Balance sheet 30 Sep 2026. Industry P/E is the median of 21 Pharmaceuticals & Biotechnology stocks.
Quarterly results
| Growth | 1Y | 3Y CAGR |
|---|---|---|
| Revenue | +0.09% | +6.34% |
| Net profit | +43.71% | — |
Trailing twelve months against the same period 1 and 3 years earlier (3Y as a yearly rate); consolidated.
| Quarter | Revenue | Net profit | YoY profit | EPS |
|---|---|---|---|---|
| Sep 2026 | ₹4,250 Cr | ₹264 Cr | −56.78% | ₹9.34 |
| Jun 2026 | ₹4,084 Cr | ₹483 Cr | +927.88% | ₹17.11 |
| Mar 2026 | ₹3,960 Cr | ₹301 Cr | +6,773.15% | ₹10.68 |
| Dec 2025 | ₹3,945 Cr | ₹403 Cr | +15.86% | ₹14.28 |
| Sep 2025 | ₹6,247 Cr | ₹610 Cr | +72.20% | ₹21.62 |
| Jun 2025 | ₹3,291 Cr | ₹46.97 Cr | −86.19% | ₹1.66 |
| Mar 2025 | ₹3,268 Cr | ₹4.38 Cr | — | ₹0.16 |
| Dec 2024 | ₹3,419 Cr | ₹348 Cr | — | ₹12.33 |
Armor risk check
GLENMARK PHARMACEUTICALS moves about 1.9× as much as the market
Volatility, past year
Worst fall, past year
Compared with the Nifty 500 over the past 12 months.
Check it against your portfolio in the appFAQs
What is GLENMARK PHARMACEUTICALS's share price today?
GLENMARK PHARMACEUTICALS (NSE: GLENMARK) closed at ₹2,671.10 on 9 Nov 2026, up 3.13% from the previous close of ₹2,590.00. It traded between ₹2,572.20 and ₹2,714.00 that day.
What are GLENMARK PHARMACEUTICALS's 52-week high and low?
Over the last 52 weeks GLENMARK PHARMACEUTICALS traded between ₹1,807.00 and ₹2,714.00, adjusted for splits and bonuses.
What are GLENMARK PHARMACEUTICALS's NSE symbol, BSE code and ISIN?
GLENMARK PHARMACEUTICALS has NSE symbol GLENMARK, BSE code 532296, ISIN INE935A01035.
How has GLENMARK PHARMACEUTICALS performed over 1, 3 and 5 years?
GLENMARK PHARMACEUTICALS's share price return: 1Y +47.45%, 3Y +50.47% a year, 5Y +38.48% a year. Dividends are not included.
Does GLENMARK PHARMACEUTICALS pay a dividend?
Yes. GLENMARK PHARMACEUTICALS's latest dividend went ex on 31 Aug 2026: Final · ₹2.50 per share. Dividends over the past year come to a yield of 0.09% at the latest close.
What is GLENMARK PHARMACEUTICALS's P/E ratio?
GLENMARK PHARMACEUTICALS's P/E ratio is 52.0: the ₹2,671.10 close on 9 Nov 2026 over trailing twelve-month EPS of ₹51.41 (consolidated, four quarters to 30 Sep 2026).
What is GLENMARK PHARMACEUTICALS's market cap?
GLENMARK PHARMACEUTICALS's market cap is ₹75,385 Cr at the close on 9 Nov 2026.
Which sector is GLENMARK PHARMACEUTICALS in?
GLENMARK PHARMACEUTICALS is in NSE's Healthcare sector, in the Pharmaceuticals & Biotechnology industry (Pharmaceuticals).
For information only. Not investment advice or a research report. Past performance does not guarantee future returns.
Full disclaimerSee how GLENMARK PHARMACEUTICALS fits your plan
Armor checks every holding against your goals, risk and timeline.
Get the app